- Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological statusDavid Morquin
Medical Intensive Care Unit, Gui de Chauliac Teaching Hospital, University of Montpellier 1, Montpellier, France
Ann Intensive Care 2:25. 2012..abstract:..
- Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2Jacques Reynes
Department of Infectious Diseases, Montpellier University Hospital, Montpellier, France
AIDS 27:1295-302. 2013..To assess the frequency of glomerular and tubular proteinuria in a cohort of HIV-infected patients, and to determine the factors associated with each type of injury...
- Suppression of HIV-1 replication by microRNA effectorsChristine Chable-Bessia
Institut de Génétique Humaine CNRS UPR1142, Laboratoire de Virologie Moleculaire, Montpellier, France
Retrovirology 6:26. 2009..Interestingly, knockdown of RCK/p54 or DGCR8 resulted in virus reactivation in PBMCs isolated from HIV infected patients treated with suppressive HAART...
- Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patientsGael Petitjean
Laboratoire de Virologie, Hopital Lapeyronie, avenue du Doyen Gaston Giraud, 34295 Montpellier, France
Retrovirology 4:60. 2007..The presence of HIV-1 preintegration reservoir was assessed in an in vitro experimental model of latent HIV-1 infection, and in patients treated or not with highly active antiretroviral therapy (HAART)...
- [Antiretroviral therapies: strategic perspectives for the future]J Reynes
Service des Maladies Infectieuses et Tropicales, UMR145 VIH er maladies associdées, CHU de Montpellier, France
Med Trop (Mars) 67:367. 2007
- TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes
Hopital Gui de Chauliac, CHU Montpellier, France
AIDS Patient Care STDS 21:533-43. 2007..In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial...
- Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapyM Segondy
Department of Virology and Department of Infectious and Tropical Diseases, Montpellier University Hospital, Montpellier, France
J Clin Microbiol 36:3392-5. 1998....
- Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 studyRoland Landman
Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
J Antimicrob Chemother 64:118-25. 2009..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients...
- Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)Sebastien Gallien
Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Department of Infectious Diseases, University of Paris Diderot Paris 7, Paris, France
J Antimicrob Chemother 66:184-91. 2011..once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine...
- Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapyM N Rousseau
Laboratory of Virology and Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire (CHU, Montpellier, France
J Acquir Immune Defic Syndr 26:36-43. 2001..In these patients, genotypic resistance tests confirm the lack of alternative salvage therapy strategies based on the currently available antiretroviral drugs...
- Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infectionPierre Portales
Laboratoire d Immunologie, Hopital Saint Eloi, Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier, France
AIDS 17:505-11. 2003..As CTL play a major role in immune defence against HIV, we wanted to further characterize CTL activity and the effect of IFNalpha on it...
- 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patientsN Bourgeois
Laboratory of Parasitology Mycology, University Hospital, Nimes, University Montpellier I, Montpellier, Nimes, France
HIV Med 11:670-3. 2010..The aim of the study was to describe a new evolutionary form of visceral leishmaniasis observed in immunocompromised patients...
- Efficacy of ceftriaxone and doxycycline in the treatment of early syphilisK C Psomas
Departement des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier Cedex, France
Med Mal Infect 42:15-9. 2012..An increase of syphilis cases has been recorded in the past few decades, especially among HIV-infected patients. These patients often present with concomitant primary and secondary lesions or extensive presentations of syphilis...
- CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progressionJ Reynes
Service des Maladies Infectieuses et Tropicales, , Montpellier, France
AIDS 15:1627-34. 2001..Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density...
- Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholaminesE Renard
The Department of Endocrinology, Lapeyronie Hospital, Montpellier, France
Clin Endocrinol (Oxf) 51:223-30. 1999..Alterations of body fat distribution have been recently reported in HIV-infected patients. We aimed to investigate whether the hormones modulating adipose tissue metabolism could be implicated...
- Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1K Triques
Laboratoire Retrovirus, ORSTOM, Montpellier, France
J Clin Microbiol 37:110-6. 1999..5, yielded accurate measurement of the HIV load for all HIV-1 subtypes tested, which should allow the test to be used to assess disease prognosis and response to antiretroviral treatment in patients infected with a group M HIV-1 subtype...
- Pregnancy may be followed by an inflexion of the immune reconstitution in HIV-infected women who receive antiretroviral drugs before conceptionV Le Moing
Centre Hospitalier Universitaire, Montpellier, France
HIV Med 9:897-900. 2008..Whether pregnancy has an impact on the evolution of CD4 cell counts in women treated with highly potent antiretrovirals before conception remains largely unknown...
- Diagnostic approaches to imported schistosomal myeloradiculopathy in travelersA Makinson
Department of Infectious Diseases, University Hospital, Montpellier, F 34295 Montpellier, France
Neurology 71:66-7. 2008
- Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patientDidier Bessis
Service de Dermatologie Phlébologie, CHU Montpellier, Hopital Saint Eloi, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
Eur J Dermatol 12:99-102. 2002..We review the literature on previously reported cases of cutaneous necrosis following standard or pegylated IFN-alpha injection and discuss the different pathophysiological mechanisms that might be involved...
- Reasons for early abacavir discontinuation in HIV-infected patientsHelene Peyriere
Pharmacovigilance Center, Lapeyronie Hospital, Montpellier, France
Ann Pharmacother 37:1392-7. 2003..To determine incidence of and reasons for discontinuation of abacavir within the first 6 months of therapy...
- Molecular diagnosis of culture-negative cerebral nocardiosis due to Nocardia abscessusHelene Marchandin
Laboratoire de Bacteriologie, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France
Diagn Microbiol Infect Dis 55:237-40. 2006..The patient is alive and well on imipenem and doxycycline therapy, 14 months after onset...
- [Antifungal treatment for suspected or proved candidiasis in the critically ill]P Massanet
Service de Reanimation Medicale, Hopital Gui de Chauliac, Centre Hospitalier Universitaire de Montpellier, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
Ann Fr Anesth Reanim 33:232-9. 2014..Describe systemic antifungal therapy in non-neutropenic adult patients in intensive care unit (ICU)...
- Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patientsS Bertout
Laboratoire de Parasitologie et Mycologie médicale UFR Pharmacie, UMI 233 UM 1 IRD UCAD UY1, Montpellier, France
Clin Microbiol Infect 19:763-9. 2013..Two genotypes may be responsible for a single episode of cryptococcosis. The possibility of mixed infection and diminished susceptibility to fluconazole or flucytosine must be considered for the management of cryptococcosis...
- Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intakeC Eiden
Department of Medical Pharmacology and Toxicology, University Hospital of Montpellier, Montpellier, France
Eur J Clin Microbiol Infect Dis 31:161-7. 2012..PCZ therapeutic drug monitoring (TDM) is essential in order to early detect patients with low concentrations, to assess the etiology of such results, and to decide on the treatment strategy to apply...
- Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemiaG J Thöni
UPRES EA 2991, Sports, Performance, Health Laboratory, Faculty of Sport Sciences, Montpellier, France
Diabetes Metab 28:397-404. 2002..The management of abdominal fat accumulation and metabolic disorders in HIV1-infected patients, by an aerobic training program, is considered...
- [Adherence to antibiotherapy guidelines for acute community-acquired pneumonia in adults, in a teaching hospital]J S Martinez
Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
Med Mal Infect 40:468-75. 2010..The authors had for aim to assess the conformity of antibiotic prescription with guidelines, for the management of community-acquired pneumonia, in a French University Hospital...
- The fusion inhibitor enfuvirtide in recent antiretroviral strategiesAlain Makinson
Infectious Diseases Department, Montpellier University Hospital, CHU Montpellier, France
Curr Opin HIV AIDS 4:150-8. 2009..The purpose of this review is to discuss recent pharmacological, virological, and clinical data that concern enfuvirtide usage in different antiretroviral combinations...
- Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimenE Tuaillon
Universite de Montpellier 1, INSERM Unité 1058, Montpellier, France
J Clin Microbiol 50:3096-8. 2012..21 to 0.09) in 12 patients experiencing HIV-1 virologic failure due to suboptimal adherence to ARV (P = 0.17). We estimated that six of these 18 patients will attain HBsAg values below 10 IU/ml after 10 years of treatment...
- [Infectious adverse events related to misuse of high-dose buprenorphine: a retrospective study of 42 cases]D Grau
Hopital Lapeyronie, Centre d Evaluation et d Information sur la Pharmacodependance, CHU de Montpellier, France
Rev Med Interne 31:188-93. 2010..Misuse of high-dose buprenorphine (HDB), mainly by injection, is responsible of frequent infectious adverse events...
- Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trialMatthieu Lafaurie
Department of Infectious Diseases, Saint Louis Hospital, University of Paris 7, INSERM U897, 1 avenue Claude Vellefaux 75010 Paris, France
J Antimicrob Chemother 62:1122-9. 2008..However, it is unclear whether patients tolerating long-term zidovudine-containing regimens will benefit from a switch to non-zidovudine-containing regimens...
- Long-term assessment of neuropsychiatric adverse reactions associated with efavirenzP Lochet
Department of Infectious Diseases, Gui de Chauliac Hospital, Montpellier, France
HIV Med 4:62-6. 2003....
- Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivoPierre Portales
Laboratoire d Immunologie, Hopital Saint Eloi, the Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier, France
AIDS 17:495-504. 2003..The aim of the present study was to better understand this defect in order to be able to restore NK function in HIV infection...
- HIV-1 reactivation in resting peripheral blood mononuclear cells of infected adults upon in vitro CD4 cross-linking by ligands of the CDR2-loop in extracellular domain 1L Briant
Laboratoire Infections Retrovirales et Signalisation Cellulaire, CRBM CRNS UPR 1086, Institut de Biologie, Montpellier, France
J Acquir Immune Defic Syndr 21:9-19. 1999..Our results indicate that the signaling events initiated in PBMCs by oligomerization of CD4 at the D1/CDR2-loop can trigger HIV-1 upregulation in infected individuals...
- Comparison of various sample preparation methods for PCR diagnosis of visceral leishmaniasis using peripheral bloodL Lachaud
, Centre Hospitalier Universitaire, , Montpellier, France
J Clin Microbiol 39:613-7. 2001....
- [Antifungal treatments of candidemia in non-neutropenic patients: evaluation of practice in intensive care units]P Massanet
Service de réanimation médicale assistance respiratoire, Hopital Gui de Chauliac, CHU de Montpellier, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
Med Mal Infect 40:644-9. 2010..The authors had for objective to assess systemic antifungal treatment for candidemia in non-neutropenic patients, in intensive care units (ICU), and compare the results with French 2004 recommendations...
- [Ocular bartonellosis in an HIV-HVC coinfected patient]C Merle De Boever
Service Maladies Infectieuses et Tropicales, CHU de Montpellier, 80 avenue Augustin Flèche, Montpellier, France
Med Mal Infect 38:504-6. 2008..Nuclear magnetic resonance revealed a retrobulbar neuritis. Confirmation was given by blood tests positive for B. henselae and the exclusion of other causes of neuroretinitis with biological data. Doxycycline cured the disease rapidly...
- Renal tubular dysfunction associated with tenofovir therapy: report of 7 casesHelene Peyriere
Department of Medical Pharmacology, Lapeyronie Hospital, CHU Montpellier, France
J Acquir Immune Defic Syndr 35:269-73. 2004..In patients with low weight or mild preexisting renal impairment, regular monitoring of tubulopathy markers could lead to early detection of this dysfunction...
- Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's diseaseAlain Makinson
Infectious Diseases Department, Gui de Chauliac Hospital, CHU Montpellier, France
Eur J Haematol 78:358-60. 2007..This unrecorded strategy is discussed...
- [Assessment of renal abnormalities in 107 HIV patients treated with tenofovir]Pierre Lochet
Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, CHU Montpellier, Montpellier, France
Therapie 60:175-81. 2005..The objectives of our study were to assess frequency, severity and outcome of renal abnormalities, as well as to determine the risk of developing hypophosphataemia in HIV-infected patients receiving tenofovir...
- The immunological response to highly active antiretroviral therapy is linked to CD4+ T-cell surface CCR5 densityThierry Vincent
J Acquir Immune Defic Syndr 43:377-8. 2006
- Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adultsDirk Schurmann
Charite Universitatsmedizin, Berlin, Germany
AIDS 21:1293-9. 2007..To determine antiviral activity, pharmacokinetic properties, and safety of vicriviroc, an orally available CCR5 antagonist, as monotherapy in HIV-infected patients...
- Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroIsabelle Malet
Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
Antimicrob Agents Chemother 52:1351-8. 2008..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired...
- Long-term persistence of memory B cells specific for hepatitis B surface antigen in HIV-1-infected patientsEdouard Tuaillon
Laboratoire de Virologie, Hopital Lapeyronie, Montpellier, France
AIDS 21:2343-5. 2007..A lower number of HBs-SC was found in HBsAg-vaccinated patients compared with vaccinated controls...
- Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick
Weill Cornell Medical College, New York, NY 10065, USA
N Engl J Med 359:1429-41. 2008..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
- Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008....
- Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendationsMike Youle
Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
HIV Clin Trials 7:86-96. 2006..g., ENF) for triple-class-experienced patients...
- The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signallingYea Lih Lin
Institut de Genetique Humaine, CNRS UPR1142, Montpellier, France
AIDS 20:1369-77. 2006....
- Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype BBrigitte Montes
Department of Virology, University Hospital of Montpellier, Montpellier, France
J Acquir Immune Defic Syndr 35:329-36. 2004..To compare the prevalence of mutations associated with resistance to antiretroviral drugs and their interpretation in patients infected with non-B HIV-1 variants versus HIV-1subtype B-infected patients with similar treatment regimens...
- T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonistsThierry Vincent
Institut de Genetique Humaine, CNRS UPR 1142, Montpellier, France
J Acquir Immune Defic Syndr 38:305-9. 2005..In conclusion, we failed to demonstrate any impact of interindividual variability in T-cell surface CCR5 density on HCV infection, which would have argued against the use of CCR5 antagonists in HIV/HCV-coinfected subjects...
- Vitamin E supplementation increases the expression of the CCR5 coreceptor in HIV-1 infected subjectsPierre Portales
Clin Nutr 23:1244-5. 2004
- Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individualsJean Michel Fondere
Laboratoire de Virologie, Hopital Lapeyronie, avenue du Doyen Gaston Giraud, 34295 Montpellier, France
J Virol 78:10536-42. 2004..The ELISPOT approach to targeting the HIV-1-Ag-SCs could be a useful method for identifying latently HIV-1-infected CD4(+) T cells carrying replication-competent HIV-1 in patients responding to HAART...
- Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20Anne Genevieve Marcelin
Pitie Salpetriere Hospital, Paris, France
AIDS 18:1340-2. 2004..Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required...
- Low CD4+ T-cell surface CCR5 density as a cause of resistance to in vivo HIV-1 infectionJacques Reynes
J Acquir Immune Defic Syndr 34:114-6. 2003
- Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapyJean Michel Fondere
Virology Laboratory, Hospital Lapeyronie, INSERM U470, Bâtiment Crastes de Paulet, Hospital A Villeneuve, France
AIDS 17:2323-30. 2003..To examine whether polyclonal activation of circulating B cells, in a process that involves CD40-CD40 ligand and cytokine interactions, could induced HIV-1-specific memory B cells to synthesize HIV-1-specific antibodies...
- Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)Christine Katlama
Département des Maladies Infectieuses et Tropicales INSERM E 0214, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
AIDS 18:217-26. 2004..Both highly potent antiretroviral drug rescue therapy and treatment interruption have been suggested to be effective in patients with multiple treatment failure...
- Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtideSharon Walmsley
University of Toronto, Toronto, Ontario, Canada
J Infect Dis 188:1827-33. 2003..Safety was unaffected by the presence of positive antibody at any time point or change in level of antibody. There was no evidence that enfuvirtide cross-reactive gp41 antibody affects the efficacy or safety of enfuvirtide...
- Enumeration of latently infected CD4+ T cells from HIV-1-infected patients using an HIV-1 antigen ELISPOT assayJean Michel Fondere
Departement de Virologie Clinique, Hopital Lapeyronie, 371 Avenue du Doyen Giraud, 34295 Montpellier edex 5, France
J Clin Virol 29:33-8. 2004..These cells serve as a potential source of reactivation of viral replication and remain a major obstacle for the eradication of HIV-1...
- Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistanceBernard Masquelier
Département de Virologie et Immunologie, Hopital Pellegrin, Bordeaux, France
J Clin Virol 33:75-8. 2005..In HIV-infected patients on first-line antiretroviral therapy, the significance of intermittent viremia and their relationship with drug resistance remain unclear...
- [New antiretroviral treatment modalities]Jacques Reynes
Service des Maladies Infectieuses et Tropicales, UMR 145 VIH et Maladies Associées Hôpital Gui de Chauliac, 34295 Montpellier
Presse Med 34:1S23-30. 2005..For non-responders, thorough virological-pharmacological assessment is necessary, together with access to new molecules and new drug classes...
- Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment dispositionXiaoping Zhang
Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
Clin Pharmacol Ther 72:10-9. 2002....
- Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeksBenoit Trottier
Clinique Médicale l Actuel, Montreal, Quebec, Canada
J Acquir Immune Defic Syndr 40:413-21. 2005..The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients...
- Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infectionYea Lih Lin
Institut de Genetique Humaine, Centre National de la Recherche Scientifique, Unité Propre de Recherche 1142, Laboratoire d Immunologie de l Hôpital Saint Eloi, France
Proc Natl Acad Sci U S A 99:15590-5. 2002..These data explain why CCR5 density influences HIV-1 disease progression and underline the therapeutic interest of lowering CCR5 expression...
- Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and AustraliaAdriano Lazzarin
Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Vita Salute University, Milan, Italy
N Engl J Med 348:2186-95. 2003....
- Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson
Chelsea and Westminster Hospital, London, United Kingdom
J Acquir Immune Defic Syndr 40:404-12. 2005....
- Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapyAnne Marie Fournier
From the Département de Virologie Clinique, Hôpitaux Lapeyronie et Saint Eloi, 34295 Montpellier Cedex 5, France
AIDS 16:1755-60. 2002....
- CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strainsYea Lih Lin
Institut de Genetique Humaine, Montpellier, France
J Acquir Immune Defic Syndr 39:530-6. 2005..027). These data suggest that CXCR4 overexpression during the course of the disease in some patients could favor the emergence of X4 strains...
- Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapyJacques Reynes
JAMA 291:46. 2004
- Nocardia veterana isolated from ascitic fluid of a patient with human immunodeficiency virus infectionSylvain Godreuil
Laboratoire de Bacteriologie, Hopital Arnaud de Villeneuve, F 34295 Montpellier cedex 5, France
J Clin Microbiol 41:2768-73. 2003..A phylogenetic analysis was conducted and showed that N. veterana was most closely related to the recently characterized species Nocardia africana rather than to Nocardia vaccinii, as previously reported...
- Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimenStephanie Badiou
Department of Biochemistry, University Hospital, Montpellier 34295, France
AIDS 17:772-4. 2003
- Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general populationMarianne Saves
INSERM U593 ex U330, Universite Victor Segalen Bordeaux 2, Bordeaux, France
Clin Infect Dis 37:292-8. 2003....
- Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?Stephanie Badiou
Department of Biochemistry, University Hospital, F34295 Montpellier, France
J Infect 52:335-8. 2006..The aim of our study was to explore the effect of tenofovir on phosphatemia and on tubular phosphate reabsorption...
- Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patientsJean Michel Fondere
Laboratoire de Virologie, Hopital Lapeyronie, Montpellier, France
J Acquir Immune Defic Syndr 35:114-9. 2004..We found that in AIDS patients, HIV-1-specific resting memory B cells circulate in the blood and can be quantified by their anti-HIV-1 antibody secretion after strong B cell polyclonal stimulation...
- Fulminant varicella hepatitis in a human immunodeficiency virus infected patient: case report and review of the literatureCatherine Lechiche
Infectious and Tropical Diseases Unit, Centre Hospitalier Gui de Chauliac, Montpellier, France
Scand J Infect Dis 38:929-31. 2006..Varicella zoster virus is an uncommon cause of acute liver disease which occurs mainly in immunocompromised patients. Acyclovir is the cornerstone of the treatment...
- Fat microinfiltration autografting for facial restructuring in HIV patientsSophie Domergue
Department of Maxillo Facial and Oral Surgery, Head Prof Dr P Goudot, University Hospital of Montpellier, France
J Craniomaxillofac Surg 34:484-8. 2006..There are several options for surgical treatment of facial lipodystrophy, one of these was described by S. R. Coleman in 1994, the technique of fat transplantation...
- Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infectionDaniel J Skiest
University of Texas Southwestern Medical Center, Dallas, Texas
Clin Infect Dis 44:607-14. 2007....
- Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latencyIsaure du Chéné
Laboratoire de Virologie Moleculaire, Institut de Genetique Humaine, UPR 1142, Montpellier, France
EMBO J 26:424-35. 2007..Finally, we show in different cellular models, including PBMCs from HIV-1-infected donors, that HIV-1 reactivation could be achieved after HP1gamma RNA interference...
- Suppression of microRNA-silencing pathway by HIV-1 during virus replicationRobinson Triboulet
Laboratoire de Virologie Moleculaire, Institut de Genetique Humaine, Montpellier, France
Science 315:1579-82. 2007..Our results highlight the involvement of the miRNA-silencing pathway in HIV-1 replication and latency...
- The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5Yea Lih Lin
Institut de Genetique Humaine, CNRS UPR1142, France
AIDS 22:430-2. 2008..Among the chemokines that bind to CCR5, and induce its internalization, CCL5 is the most abundant in vivo. We show that the level of CCL5 production is a main factor determining CD4+ T cell surface CCR5 density...
- Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapyAntoine Berry
Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Centre Hospitalier Universitaire, 34295 Montpellier Cedex 5, France
Scand J Infect Dis 36:225-7. 2004..The report raises the question whether a rapid immune reconstitution may convert a latent visceral leishmaniasis into a symptomatic one...
- Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapyJean Marie Bard
Faculte de Pharmacie, Laboratoire de Biochimie, Nantes, France
Antivir Ther 11:361-70. 2006....
- Introduction of SARS in France, March-April, 2003Jean Claude Desenclos
Département Maladies Infectieuses, Institut de Veille Sanitaire, Saint Maurice, France
Emerg Infect Dis 10:195-200. 2004..Timely detection, isolation of probable case-patients, and quarantine of their contacts appear to have been effective in preventing the secondary spread of SARS in France...
- Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adultsStephanie Badiou
Laboratoire de Biochimie des Lipides, Department of Biochemistry, 371 Av du Doyen Gaston Giraud, Hopital Lapeyronie, CHU Montpellier F34295, France
Atherosclerosis 172:273-9. 2004..This study evaluates the effects of fenofibrate and/or Vitamin E on lipoprotein profile...
- Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cellsAnne Marie Fournier
Departement de Virologie Clinique, Centre Hospitalier et Universitaire, Montpellier, France
Clin Immunol 103:98-109. 2002....